Pediatric Respiratory Diseases: Diagnosis, Treatment, and Prevention
A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Pulmonary and Sleep Medicine".
Deadline for manuscript submissions: 15 January 2025 | Viewed by 1663
Special Issue Editor
Special Issue Information
Dear Colleagues,
The field of pediatric respiratory medicine has undergone explosive development in the last decade. The COVID-19 pandemic has brought about the development of new vaccine technologies that we hope will be useful in protecting against other important pathogens of common respiratory diseases such as respiratory syncytial virus. In the area of prevention, neonatal screening for cystic fibrosis is also being implemented in a growing number of countries. The biggest breakthroughs have been made in the treatment of cystic fibrosis, with the introduction of chloride channel modulators into clinical practice. New guidelines in the treatment of asthma bring about a paradigm shift from continuous to intermittent therapy with inhaled corticosteroids.
This Special Issue of Children aims to contribute new insights into the prevention, diagnostics and treatment of infectious respiratory diseases, asthma, cystic fibrosis and other chronic respiratory diseases in children. Hence, we enthusiastically invite submissions of both original research and reviews focusing on cutting-edge scientific advancements within these domains.
Dr. Vojko Berce
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- respiratory disease
- children
- lower respiratory tract infection
- asthma
- cystic fibrosis
- prevention
- diagnostics
- treatment
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Evaluation and comparison of the efficacy of subcutaneous and sublingual immunotherapy for the treatment of allergic asthma in children
Authors: Vojko Berce; Maša Cugmas; Staša Čopi; Brigita Koren; Maja Tomazin; Tina Hojnik
Affiliation: Department of Pediatrics, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia
Abstract: Specific immunotherapy represents the only causal treatment for allergic asthma. The allergen can be administered subcutaneously (SCIT) or sublingually (SLIT). Therefore, we aimed to evaluate and compare the efficacy of SCIT and SLIT for the treatment of allergic asthma in children. We included 69 children with allergic asthma who underwent immunotherapy for house dust mite or pollens for at least 3 consecutive years. After 3 years of SCIT and SLIT, the median number of asthma exacerbations in the last three months decreased from 2 to 0 (p < 0.01) and from 1 to 0 (p < 0.01), respectively. When comparing the efficacy of SCIT and SLIT, we found a significantly better efficacy of SCIT only in terms of lung function increase. The median increase in FEV1 after 3 years was 8% with SCIT and -1% with SLIT (p < 0.01). Daily controller therapy could be withdrawn or reduced in 14 out of 16 (87.5%) children receiving it before SCIT (p < 0.01) and in 19 of 29 (65.6%) children receiving it before SLIT (p < 0.01), but the difference in efficacy was not significant (p = 0.50). Both SCIT and SLIT are effective treatments for allergic asthma in children.
